Premium
Long‐term results of the MCL01 phase II trial of rituximab plus HyperCVAD alternating with high‐dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma
Author(s) -
Massaro Fulvio,
Stepanishyna Yana,
Manni Martina,
Luminari Stefano,
Galimberti Sara,
Marcheselli Luigi,
Visco Carlo,
Tecchio Cristina,
Stelitano Caterina,
Angrilli Francesco,
Petrini Mario,
Merli Francesco,
Federico Massimo
Publication year - 2021
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.16714
Subject(s) - medicine , vincristine , mantle cell lymphoma , cytarabine , rituximab , cyclophosphamide , regimen , surgery , autologous stem cell transplantation , methotrexate , gastroenterology , oncology , transplantation , chemotherapy , lymphoma
Summary Mantle cell lymphoma is a rare and incurable lymphoproliferative disorder. In the MCL01 trial, patients were treated with the R‐HCVAD regimen [rituximab plus HyperCVAD (hyperfractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone; R‐CVAD) alternating with high‐dose methotrexate and cytarabine (AM)] for four cycles followed by autologous stem cell transplantation (ASCT) for those who reached only a partial response. After a median follow‐up of 10·5 years, we reported 10‐year progression‐free and overall survival rates of 35% and 61% respectively, with a 10‐years cumulative incidence rate of second malignancies of 10·6%. Mature results of the MCL01 trial confirmed the efficacy of HyperCVAD‐AM as a frontline regimen for younger patients (≤65 years).